SLC35A2 and Hypoxemia: Hypoxemia can interfere with the oxygen-demanding steps of nintedanib metabolism (such as glucuronidation by UGT-enzymes) in hepatocytes, thereby retarding the clearance of potentially harmful metabolites [35, 62].